MeiraGTx
Vertically integrated, clinical-stage gene therapy company developing transformative treatments for severe diseases using proprietary AAV gene therapy platform, with a focus on inherited retinal diseases and other rare conditions.
Notes
MeiraGTx is a vertically integrated, clinical-stage gene therapy company focused on developing potentially curative treatments for patients with serious diseases. The company has built proprietary capabilities across the entire gene therapy value chain, from vector design through manufacturing and clinical development.
Listed on NASDAQ under the ticker MGTX, MeiraGTx's lead programs focus on inherited retinal diseases (IRDs), with additional programs in xerostomia (severe dry mouth) and neurodegenerative diseases. The company operates its own AAV manufacturing facilities to ensure supply chain control.
Team
- Alexandria Forbes, Ph.D. - President & Chief Executive Officer
- LinkedIn: linkedin.com/in/alexandria-forbes
- Luk Vandenberghe, Ph.D. - Chief Scientific Officer
- Richard Giroux - Chief Operating Officer
Additional Research Findings
- Founded in 2015
- Headquarters in New York City with operations in London
- Listed on NASDAQ (MGTX)
- Vertically integrated gene therapy platform
- Proprietary AAV manufacturing capabilities
- Lead programs in inherited retinal diseases
- Collaboration with Janssen on AAV technologies
- Shannon, Ireland manufacturing facility
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| AlbionVC (Healthcare) | London, UK | biotech-focused | seedseries-a+1 | 17 |